UK-listed drugs company GlaxoSmithKline’s (GSK) new strategic corporate venturing fund for bioelectronic medicines and technologies has joined a consortium to investing in the $27m series D round for SetPoint Medical, a US-based biomedical technology company.
Alongside GSK’s Action Potential Venture Capital fund in the round were corporate venturing peers from healthcare companies Covidien and Boston Scientific and venture capital firms Morgenthaler Ventures, Foundation Medical Partners, which has Cleveland Clinic as a strategic limited partner, and Topspin Partners.
The three venture…
